Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03499808 · ClinicalTrials.gov registry record · Phase 2
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03499808 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 43 participants.
The verdict
NCT03499808, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Isatuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2023-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03499808
The ClinicalTrials.gov registry entry for NCT03499808 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03499808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03499808 about?
NCT03499808 is a clinical study titled "S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis". This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.
What is the current status of trial NCT03499808?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-06-06. Estimated completion is 2023-09-19.
What interventions are being tested in trial NCT03499808?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Isatuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03499808?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.